← Eichor
Study identifier: NCT07276542 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Clinical Trial Exploring the Outpatient Treatment of Phantom Limb Pain With Ketamine Administration in a Six Month Study With a Minimum Remission Period of 7 Days Between Treatment Session. 25-30 Subjects With an Ongoing History of Significant PLP.--FDA and IRB Approved.

Condition: Phantom Limb Syndrome With Pain  ·  Sponsor: The Ketamine Research Foundation

PhasePhase 2/Phase 3
Planned participants30
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

Must be living Within a 50 mile radius of our study sites: Bay Area, Los Angeles, Albuquerque, Sacramento, Los Angeles An anecdotal report with administration of ketamine in a non-clinical setting providing and sustained remission of symptoms after 6 years has furthered the interest in ascertaining if ketamine might indeed be a successful intervention. (See Wolfson and Barocchi). Ketamine has shown benefit in a variety of pain and neurological disorders. Its exploration for these continues and there appears to be an expanding use of ketamine for difficult to treat syndromes. Phantom limb pain occurs in over 50% of amputees, tends to be immediate in onset, but may occur at a later time. It is often excruciating, with a high frequency of episodes that tend to diminish with time-- variably. Its treatment is reliant on opioids and other pain medications usually with limited results. Acupuncture has been minimally explored with no clear results. Our study aims at clarifying ketamine's status for this particular disorder. This is an off-label use of RS ketamine for clinical purposes. Each subject of the 25-30 enrolled in the study will have up to 16 ketamine sessions over six months time, Subjects will be continued in the study if the partial or complete remission period is seven days or more, If less, subjects will be considered to have not adequately responded to the protocol's provision of IM ketamine. Dosage of ketamine will be determined in the initial session with a dosage…

This description comes directly from the study's public registry record.

Talk to the study team

Philip E Wolfson, MD  ·  +1-415-785-3797  ·  ketamine.research@gmail.com

Gabriel Klapman, MD  ·  415-785-3797  ·  ketamine.research@gmail.com

Always discuss trial participation with your own doctor first.

Locations (4)

ShamyndsSacramento, California, United StatesRecruiting
Ketamine Research FoundationSan Anselmo, California, United StatesRecruiting
Mystic HealthSanta Monica, California, United StatesRecruiting
Lisa Feierman MDAlbuquerque, New Mexico, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07276542